What this pack is
RAYOS is the brand name in this record; prednisone is the generic name. Read both together with the dosage form (oral tablet).
PACK CHECK · MARKET FIRST
RAYOSGeneric nameprednisone
How this medicine works
Prednisone is converted in the body to active prednisolone and produces broad anti-inflammatory and immune effects through glucocorticoid-related pathways. RAYOS's key product difference is delayed release from the intact coating. That does not mean constant all-day release or prove that it is stronger, safer or suitable for an individual compared with immediate-release prednisone.
Read source: United States ↗reviewed 2026-08-29More about its action and precautions →Check the market, names, dosage form and route together
A medicine may use different brand names across markets. Keep the market, brand, generic name, dosage form and route together; one matching field does not prove that two packs are the same or interchangeable.
Open the complete product-identity record
Use these fields when the pack, market name or package image needs closer checking. They are evidence boundaries, not substitution instructions.
- International brand name
- RAYOS
- Generic name
- prednisone
- Dosage-form class
- Prednisone delayed-release tablets: 1 mg, 2 mg or 5 mg per tablet; six historical bottle identities; not a regular immediate-release prednisone tablet and not a synonym for constant all-day release
- Route
- Oral
- Package-image status
- No exact original-brand package image is shown This is deliberate: do not use a retailer, repackager or another-market image to identify the pack in hand. See why and what to check instead →
No source-verifiable mainland-China trade-name cue has been established for this record. This does not establish whether the medicine exists, is approved or is available in mainland China. Check pack text and current CDE/NMPA records item by item.
FOR EVERYDAY QUESTIONS
After the leaflet, continue with the question you still need to check
What this page can show
This is a source-traceable public record. It helps you read the product identity and its listed source documents; each market still needs its own current record check.
What to bring to the next conversation
Bring the actual pack, the label or prescription, and a complete medicine list when you speak with a pharmacist or clinician.
NEXT SAFE STEP
Choose the next safe check
A question about changing, combining or splitting?Put the exact packs on one list before a pharmacist or prescriber checks the full context.Open the family medicine list →A question about cost, reimbursement or availability?First lock the market, exact presentation and date. Use local official reimbursement, hospital or pharmacy channels for a current answer rather than a web estimate.Open regulator and market-record entry points →Unsure about a pack or a cross-border product?Photo reading can return possible record matches only. Check the actual product against the current regulator record for its market.Identify pack text locally →Saw a recall, approval or procurement headline?Open the original publisher, then match its product, market and date. Do not make a stop or switch decision from a headline.Read primary-source news →
PRODUCT PRESENTATION IDENTITY
Strength, pack and device identity
Package strength is not an individual dose. These fields help identify the exact labelled product; they do not calculate how much, how often, a missed-use action, splitting, switching or conversion.
How to read a score line: ‘scored’ or ‘unscored’ first identifies this labelled presentation. A score line by itself does not permit self-splitting, reducing or changing the product. Only an explicit statement in the current label for this exact presentation, checked with a pharmacist against the prescription, can support any further handling.
6 source-backed strength, pack or device records — open the full list
First match the market, dosage form and labelled amount on the pack in hand. The number of tablets, sachets or devices in a pack is not a personal dose or schedule.
United States label · Dated U.S. FDA prescribing information (revised Jun 2024; SUPPL-013)
Prednisone 1 mg per tablet; 30-tablet bottle; U.S. brand product discontinued
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 75987-020-01
- Form and route
- RAYOS prednisone delayed-release oral tablet · oral (intact delayed-release tablet identity field)
- Container
- bottle
- Listing review
- Cited product evidence reviewed 2026-08-29; actual marketing, stock and availability are not established.
- prednisone
- 1 mglabelled amount per tablet; not an individual's tablet count, timing, taper or stopping instruction
- Package
- 30 tablets per bottle
- Labelled appearance
- pale yellowish-white · pale yellowish-white, round and unscored; debossed NP on one side and 1 on the other; the delayed-release coating must remain intact · imprint NP / 1Unscored; do not infer permission to split it
United States label · Dated U.S. FDA prescribing information (revised Jun 2024; SUPPL-013)
Prednisone 1 mg per tablet; 100-tablet bottle; U.S. brand product discontinued
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 75987-020-02
- Form and route
- RAYOS prednisone delayed-release oral tablet · oral (intact delayed-release tablet identity field)
- Container
- bottle
- Listing review
- Cited product evidence reviewed 2026-08-29; actual marketing, stock and availability are not established.
- prednisone
- 1 mglabelled amount per tablet; not an individual's tablet count, timing, taper or stopping instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- pale yellowish-white · pale yellowish-white, round and unscored; debossed NP on one side and 1 on the other; the delayed-release coating must remain intact · imprint NP / 1Unscored; do not infer permission to split it
United States label · Dated U.S. FDA prescribing information (revised Jun 2024; SUPPL-013)
Prednisone 2 mg per tablet; 30-tablet bottle; U.S. brand product discontinued
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 75987-021-01
- Form and route
- RAYOS prednisone delayed-release oral tablet · oral (intact delayed-release tablet identity field)
- Container
- bottle
- Listing review
- Cited product evidence reviewed 2026-08-29; actual marketing, stock and availability are not established.
- prednisone
- 2 mglabelled amount per tablet; not an individual's tablet count, timing, taper or stopping instruction
- Package
- 30 tablets per bottle
- Labelled appearance
- yellowish-white · yellowish-white, round and unscored; debossed NP on one side and 2 on the other; the delayed-release coating must remain intact · imprint NP / 2Unscored; do not infer permission to split it
United States label · Dated U.S. FDA prescribing information (revised Jun 2024; SUPPL-013)
Prednisone 2 mg per tablet; 100-tablet bottle; U.S. brand product discontinued
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 75987-021-02
- Form and route
- RAYOS prednisone delayed-release oral tablet · oral (intact delayed-release tablet identity field)
- Container
- bottle
- Listing review
- Cited product evidence reviewed 2026-08-29; actual marketing, stock and availability are not established.
- prednisone
- 2 mglabelled amount per tablet; not an individual's tablet count, timing, taper or stopping instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- yellowish-white · yellowish-white, round and unscored; debossed NP on one side and 2 on the other; the delayed-release coating must remain intact · imprint NP / 2Unscored; do not infer permission to split it
United States label · Dated U.S. FDA prescribing information (revised Jun 2024; SUPPL-013)
Prednisone 5 mg per tablet; 30-tablet bottle; U.S. brand product discontinued
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 75987-022-01
- Form and route
- RAYOS prednisone delayed-release oral tablet · oral (intact delayed-release tablet identity field)
- Container
- bottle
- Listing review
- Cited product evidence reviewed 2026-08-29; actual marketing, stock and availability are not established.
- prednisone
- 5 mglabelled amount per tablet; not an individual's tablet count, timing, taper or stopping instruction
- Package
- 30 tablets per bottle
- Labelled appearance
- light yellow · light yellow, round and unscored; debossed NP on one side and 5 on the other; the delayed-release coating must remain intact · imprint NP / 5Unscored; do not infer permission to split it
United States label · Dated U.S. FDA prescribing information (revised Jun 2024; SUPPL-013)
Prednisone 5 mg per tablet; 100-tablet bottle; U.S. brand product discontinued
Source-text identity card: no displayable exact official package image. The fields below come from the cited label and are not a visual authentication result.
- Product code
- NDC 75987-022-02
- Form and route
- RAYOS prednisone delayed-release oral tablet · oral (intact delayed-release tablet identity field)
- Container
- bottle
- Listing review
- Cited product evidence reviewed 2026-08-29; actual marketing, stock and availability are not established.
- prednisone
- 5 mglabelled amount per tablet; not an individual's tablet count, timing, taper or stopping instruction
- Package
- 100 tablets per bottle
- Labelled appearance
- light yellow · light yellow, round and unscored; debossed NP on one side and 5 on the other; the delayed-release coating must remain intact · imprint NP / 5Unscored; do not infer permission to split it
PACKAGE-VISUAL STATUS
Historical label text verifies colour, imprint, strength, NDC and bottle count; text-only appearance is not presented as a current package image
The 2024 FDA label lists three round unscored tablets and six historical bottle NDCs, but this review did not obtain an official principal display panel safely matched one-to-one to every pack. Because Drugs@FDA now lists the products as discontinued, the page shows traceable text identity and an enlarged label without substituting retail, resale or another prednisone product image.
LABEL READING · NOT A PRESCRIPTION
RAYOS label reading: delayed release is not a regular tablet, and the coating must remain intact
Reading level: drug-specific label reading. This record has been expanded around its dosage form or a higher-risk reading question; the current target-market label and professional review still apply.
The dated FDA label requires the tablet to be swallowed whole with food and says not to break, divide or chew it. Label in-vitro testing describes an approximately four-hour delay before release begins; this explains dosage-form identity and is not anyone's timing, make-up-dose or switching instruction.
- 1, 2 and 5 mg are labelled amounts per delayed-release tablet, not tablets per dose. Although two 1 mg numbers add arithmetically to 2 mg, that does not permit self-substitution for one 2 mg tablet, prescription assembly or a change to a taper.
- Do not self-break, cut, crush or chew RAYOS. It is unscored and the label explains that delayed release depends on an intact coating. If swallowing is difficult or the prescription needs a lower strength, ask the pharmacist or prescriber to review the exact product and feasible options.
- Do not abruptly stop, copy another person's taper, or self-convert milligrams with MEDROL, dexamethasone or regular prednisone. Corticosteroid, release pattern, duration and individual circumstances differ; stopping or conversion requires the treating professional.
- Infection exposure or fever, vision change, marked mood or behaviour change, black stools or vomiting blood, severe abdominal pain, marked swelling or breathlessness need prompt medical contact. Breathing difficulty, swelling of the face/lips/tongue/throat, fainting or another critical feature requires immediate local emergency care.
- Older adults and people with diabetes, hypertension, osteoporosis, gastrointestinal disease, kidney or liver impairment or higher infection risk should have these factors and the complete medicine list reviewed. Warfarin, aspirin/NSAIDs, diuretics, digoxin, diabetes medicines, rifampin, phenytoin, ketoconazole, cyclosporine, oestrogens, supplements and herbal products all belong on that list.
PHARMACOVIGILANCE · OFFICIAL ROUTES
Check safety information in the right market
Start with the public label or product record linked to this dossier, then use the official safety routes below for the market that applies to the medicine in hand.
Match five details before using a safety record
- Brand and generic nameBoth must match the medicine named by the record.
- Dosage form and strengthTablet, capsule, injection, inhaler, patch and eye drop are not interchangeable.
- Market and notice dateA record applies only to the country or region and date it names.
- Lot, pack and manufacturerRecord these only when the official notice specifically names them.
- Current product informationA historical record may have been superseded by the current label.
This checklist only helps organise the right question. It does not create a personal conclusion about stopping, switching, dose, combination or suitability.
This dossier’s product-level source checkFDA · United States · Regulatory product record or label archive · 2026-08-29
This dossier’s publicly accessible product-level route has been checked individually. It does not mean that real-time alerts in every country or region have been searched, or that the medicine has or does not have a current risk.
Markets actually represented by the reviewed product documents
- United States · 2
This is a document-coverage summary, not a claim that the medicine is authorised, supplied, interchangeable or actively monitored in every listed market today.
This record’s label or product-record routeFDA: RAYOS (prednisone) delayed-release tablet U.S. prescribing information (NDA 202020; revised Jun 2024) ↗reviewed 2026-08-29
Other official market or version documents for this record
These are separately reviewed product documents for the same dossier. Their market, date, dosage form and document status must stay attached to each link; they do not establish interchangeability between products, strengths, packs, indications or countries.
- FDA · United States · Regulatory product record or label archive · 2026-08-29FDA Drugs@FDA: current RAYOS (prednisone) NDA 202020 application record; 1 mg, 2 mg and 5 mg are listed as Discontinued and RLD as Yes ↗Current regulatory record · reviewed 2026-08-29
This is not a conclusion that the medicine has no risk, warning, recall or newer notice in another market. Start with the checked product-level label above, then use the official market gateways below for the product in hand.
See the reviewed safety-record directory →Global official safety gateways
- NMPA Centre for Drug Reevaluation · Mainland ChinaPrimary NMPA Drug Evaluation Centre gateway for drug-vigilance bulletins, safety notices and adverse-reaction monitoring. Exact products still require checking approval number, dosage form, strength, authorisation holder and notice date item by item.Drug-vigilance bulletins and safety notices ↗reviewed 2026-08-22
- FDA · United StatesPrimary FDA pages for important new safety issues, labelling changes and risk communications.Drug Safety Communications ↗reviewed 2026-08-22
- FDA MedWatch · United StatesU.S. MedWatch safety-information and reporting gateway; a report does not itself establish causality.Safety information and serious-problem reporting ↗reviewed 2026-08-22
- EMA · European Union / European Economic AreaOfficial EU gateway for pharmacovigilance, suspected adverse-reaction reports and PRAC safety assessment.Pharmacovigilance overview and EudraVigilance ↗reviewed 2026-08-22
- MHRA · United KingdomPrimary UK MHRA medicine-safety updates for professionals and the public.Drug Safety Update ↗reviewed 2026-08-22
- PMDA · JapanPMDA’s English official safety gateway; exact products still require checking against the Japanese product page and current documents.Medicine safety information ↗reviewed 2026-08-22
- MFDS · Republic of KoreaMFDS’s primary index for medicine safety letters in the Republic of Korea. The original notices are in Korean and must be read against the named product, dosage form, market and date; they do not automatically apply in another market or decide an individual case.Medicine safety letters ↗reviewed 2026-08-22
- HSA · SingaporeHSA’s public Singapore gateway for suspected adverse-event reporting and medicine-safety information. A report does not itself establish individual causality; exact products still require checking Singapore registration status, dosage form, strength, date and current product information.Adverse-event reporting and medicine-safety information ↗reviewed 2026-08-22
- Health Canada · CanadaHealth Canada’s public MedEffect gateway for medicine and health-product advisories, warnings, recalls, reporting and safety information. Exact products still require checking market, dosage form, strength, notice date and lot item by item.MedEffect Canada: advisories, warnings and recalls ↗reviewed 2026-08-22
- TGA · AustraliaPrimary Australian TGA safety alerts, advisories and monitoring information for therapeutic products.Medicine safety alerts ↗reviewed 2026-08-22
- Swissmedic · SwitzerlandOfficial Swissmedic gateway for pharmacovigilance, signal assessment and suspected adverse-reaction reporting; a report or signal does not itself confirm individual causality.Pharmacovigilance and suspected adverse-reaction reporting ↗reviewed 2026-08-22
- Medsafe · New ZealandNew Zealand Medsafe gateway for public and professional medicine safety communications and archives; older notices may have been superseded by current product information.Medicine safety communications ↗reviewed 2026-08-22
- SAHPRA · South AfricaSAHPRA’s safety-information, alerts and pharmacovigilance gateway for the public and professionals in South Africa. An official alert does not itself mean a product is unsafe in every circumstance; exact products still require checking South African registration status, dosage form, strength, notice date and current product information.Medicine safety information, alerts and pharmacovigilance ↗reviewed 2026-08-22
- WHO · GlobalWHO’s cross-market safety-alert archive; every historical notice must be read against its date, named product and market.Medicine and vaccine safety-alert archive ↗reviewed 2026-08-22
- Anvisa · BrazilAnvisa’s primary Brazilian pharmacovigilance gateway for alerts, bulletins, risk communication and VigiMed reporting. Exact products still require checking Brazilian authorisation status, dosage form, strength and notice date item by item.Pharmacovigilance, alerts and VigiMed ↗reviewed 2026-08-22
This card brings together the medicine-specific product route and 15 market-level official vigilance gateways. It does not mean real-time alerts for this medicine have been searched in every country or region, or that the medicine has a new alert, recall or risk conclusion. Match brand, generic name, dosage form, strength, market and notice date item by item; do not self-stop, switch, increase or reduce use from a headline.
For severe or rapidly worsening symptoms, suspected overdose, a severe allergic reaction, loss of consciousness or another emergency, use local emergency services. Do not wait for an online alert search or change a medicine from this page.
PRIVATE FAMILY LIST
Bring this record into a local medicine list
Only the brand, generic name, dosage form and route are added, and they stay in this browser. Copy strength, label directions, start/stop history and any concern from the actual pack; this tool does not calculate a dose or decide combination, switching or stopping.
Add to the family medicine list →PACK · LABEL · MEDICINE LIST
Six checks for this medicine pack
Use this card to organise questions about RAYOS (prednisone). Keep the exact pack, its current label and the full medicine list together.
Identify the exact product
RAYOS is the brand in this record and prednisone is the active-ingredient name. Check both with the dosage form (Prednisone delayed-release tablets: 1 mg, 2 mg or 5 mg per tablet; six historical bottle identities; not a regular immediate-release prednisone tablet and not a synonym for constant all-day release) and the market on the actual pack.
Read the labelled strength in context
mg, mcg, mg/mL or a percentage describes the labelled amount in one tablet, capsule, measured volume, spray or other unit. It is not an answer to how many units a person should take.
Check before splitting or opening
Before splitting, crushing, chewing or opening anything, find an explicit instruction for this exact product in its current label and ask a pharmacist. A score line or a previous pack is not enough by itself.
Put every product on one list
Include prescriptions, over-the-counter products, eye drops, creams, vitamins, minerals, herbs and supplements. A pharmacist or prescriber needs the whole list before any combination, alternation, switch or stop is considered.
Ask a specific pharmacogenetics question
Ask which medicine, which gene and what clinical decision a result could change. A gene–drug association does not mean broad genetic testing is needed for everyone and must not be used to change treatment without professional review.
Know when to seek urgent help
For a suspected overdose, a severe allergic reaction, fainting or difficulty breathing, use the local emergency or poison-information service now. Do not wait for a website reply or alter several medicines to test what caused it.
This card does not calculate a dose, decide whether medicines can be combined, or replace a clinician or pharmacist. Market-specific current labels and the person's full context still need review.
MARKET DOCUMENTS · READ SEPARATELY
Enlarged market leaflets and regulator documents
Each link retains its own market, date, dosage form and document status. These documents support larger-print reading and item-by-item checking; they do not make products, strengths, packs, indications or use between countries or regions interchangeable.
- FDA: RAYOS (prednisone) delayed-release tablet U.S. prescribing information (NDA 202020; revised Jun 2024) ↗reviewed 2026-08-29
- FDA Drugs@FDA: current RAYOS (prednisone) NDA 202020 application record; 1 mg, 2 mg and 5 mg are listed as Discontinued and RLD as Yes ↗Current regulatory record · reviewed 2026-08-29
HOW IT WORKS · NOT A TREATMENT PLAN
How RAYOS works: prednisone is converted in the body for glucocorticoid effects, while delayed release changes the release timing
- Delayed release means that release onset is postponed; it does not mean sustained release, constant all-day release or every product labelled ER/XR/SR/MR. Check the exact brand, dosage form and label.
- The FDA original review records pharmacokinetic and food-effect differences from immediate-release prednisone, but that dosage-form difference must not be rewritten as superior efficacy, self-convertibility or a way around a prescription.
- The site explains product identity and the official label only. Indication, timing, amount, duration, taper and stopping must return to the exact prescription and professional review of the condition, duration of use, prior reactions and all medicines.
SOURCE EVIDENCE REGISTER
Source evidence map
Every public link is labelled with its market, document status and document type. A historical public record is not a current label, and an official lookup entry is not a product-specific record.
- FDA: RAYOS (prednisone) delayed-release tablet U.S. prescribing information (NDA 202020; revised Jun 2024) ↗reviewed 2026-08-29
- FDA Drugs@FDA: current RAYOS (prednisone) NDA 202020 application record; 1 mg, 2 mg and 5 mg are listed as Discontinued and RLD as Yes ↗Current regulatory record · reviewed 2026-08-29
- FDA: RAYOS NDA 202020 original review summary (2012; 505 (b)(2) delayed-release prednisone) ↗reviewed 2026-08-29
- FDA: RAYOS NDA 202020/S-013 supplemental approval letter (5 Jun 2024) ↗reviewed 2026-08-29
SOURCE-TRACEABLE ARCHIVE
RAYOSprednisone
This page links to public primary-source material for RAYOS. The archive is historical or documentary evidence only; it does not by itself establish originator status, product quality, current labelling, availability or sale eligibility.
DOCUMENT TIMELINE
Document timeline
FDA approved RAYOS delayed-release tablets
The FDA original review evaluated this 505(b)(2) NDA against an immediate-release prednisone reference and recorded delayed-release and food effects. This node traces product design and approval; it is not a current-supply or comparative-efficacy conclusion.
FDA: RAYOS NDA 202020 original review summary (2012; 505(b)(2) delayed-release prednisone) ↗FDA approved the SUPPL-013 label update
The FDA approval letter and Jun 2024 prescribing information are the most recent dated label node reviewed here. A document date is not evidence of stock or relaunch.
FDA: RAYOS NDA 202020/S-013 supplemental approval letter (5 Jun 2024) ↗Current Drugs@FDA application status reviewed
The current NDA 202020 application page lists all 1, 2 and 5 mg delayed-release tablets as Discontinued and RLD as Yes. This is the site's review date, not a regulatory-decision date.
FDA Drugs@FDA: current RAYOS (prednisone) NDA 202020 application record; 1 mg, 2 mg and 5 mg are listed as Discontinued and RLD as Yes ↗
MARKET SCOPE
Market-record boundary
United States
Historical RLD archive; 1 mg, 2 mg and 5 mg are currently listed as DiscontinuedThe page retains the most recent dated FDA label, six historical bottle identities and current application status. It is not a finding of stock, purchasing route, relaunch or individual suitability.
Mainland China, EU, Japan and other markets
Current market record not establishedNo local trade name, approval, packaging, supply, originator/generic relationship or interchangeability is inferred from the U.S. RAYOS brand, NDA, RLD identity, generic name or appearance.
How to read this record
Read each document in its stated market, date and dosage-form context. A historical record is not a current label and does not support individual medical, substitution or purchasing conclusions.
Keep international and mainland China records separate
This page has a U.S. public history/regulatory archive but no mainland China record for this specific product. That does not establish whether the medicine exists, is approved or is available in mainland China. Verify product identity, dosage form, strength, holder and the current label item by item.
RECORD FAQ
Record questions
Is RAYOS an extended-release tablet that releases all day?
Its exact form is delayed release: the intact coating postpones the start of release. It is not equivalent to every sustained-, controlled- or extended-release product, and constant all-day release cannot be inferred. Use the full brand, dosage form and official label when checking it.
Can a 1 mg tablet be split in half to make 0.5 mg?
Do not do this yourself. The RAYOS label describes an unscored tablet and requires swallowing whole without breaking, dividing or chewing because delayed release depends on the intact coating. If a lower strength or change is needed, ask the pharmacist or prescriber to review the exact prescription and available product.
If FDA still has a label, is RAYOS still available?
No. The current Drugs@FDA application page lists all three strengths as Discontinued. A retained label and NDA are regulatory-record facts, not stock, purchasing eligibility or relaunch conclusions.
READ NEXT
Related reading
Evidence status
The listed links are public sources selected for traceability. They must be rechecked against the current target-market record before any use beyond reading and research.